Evotec extends Huntington's collaboration; Cellerant lands $47.5M BARDA contract; Mimetogen touts dry eye syndrome trial data;

@FierceBiotech: Gates Foundation adds $50M to help speed Ebola drug development efforts. Story | Follow @FierceBiotech

@JohnCFierce: Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets - via @TracyStaton. Article | Follow @JohnCFierce

@DamianFierce: Biotech's sprawling PED scandal widens as @adamfeuerstein admits that he "juices" daily. Report | Follow @DamianFierce

@EmilyMFierce: Uh oh. Survival rate of Ebola may be less than what we think. More from Science | Follow @EmilyMFierce

Germany's Evotec AG has extended its collaboration with the CHDI Foundation, gaining funding for 52 scientists working on Huntington's disease. Release

San Carlos, CA-based Cellerant Therapeutics has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority. The money will be earmarked for CLT-008, a cell-based therapy for hematopoietic sub-syndrome of Acute Radiation Syndrome. Release

Montreal-based Mimetogen Pharmaceuticals says it garnered positive top line data from its second clinical study with MIM-D3, its lead drug for the treatment of dry eye syndrome. Release

Medical Device News

@FierceMedDev: Med tech M&A beware: Top Senate Democrats reveal plan to crack down on inversions. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: ACLA head makes case against FDA LDT regulation to Congress. Story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Top Senate Democrats unveil plans to curb corporate tax inversions. Reuters story | Follow @EmilyWFierce

> Harvard gets DARPA grant to develop soft, mobility exosuit. More

> Blackberry to integrate medical devices in India. Article

> Med tech M&A beware: Top Senate Democrats reveal plan to crack down on inversions. Story

Pharma News

@FiercePharma: Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients. News | Follow @FiercePharma

@EricPFierce: Merck & Co is again shipping BCG vaccine but Sanofi is not. Story | Follow @EricPFierce

@CarlyHFierce: FDA approves Sanofi's Menactra as meningococcal booster. More | Follow @CarlyHFierce

> Takeda preps to launch Orexigen's obesity drug Contrave as Novo's Saxenda looms. Story

> Meet Baxalta, the pharma spinoff Baxter plans to unleash in 2015. Article

> The huge price hike as sales strategy, taken to extremes by Retrophin. News

Vaccines News

> Glaxo's Ebola vaccine passes key animal test as human trials begin. News

> Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients. More

> New problems at GSK flu vaccine plant will impact U.S., Canada orders. Story

> Takeda on track for dengue vaccine nods in 2017-18. Article

> FDA approves Sanofi's Menactra as meningococcal booster. Item

Pharma Manufacturing News

> Apotex recalls Paxil tainted at GSK plant. Story

> Sources: FDA inspectors in Sun plant that has had recalls. More

> FDA fight with compounder tests its patience and its limits. Article

> Hospira will prep Indian workers at Vizag 'university.' Story

> Merck again shipping BCG cancer treatment but Sanofi still is not. Report

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.